Erica Crannage, Pharm.D., BCPS, BCACP Clinical Pharmacist/Associate [PDF]

SLIDE 1

Erica Crannage, Pharm.D., BCPS, BCACP Clinical Pharmacist/Associate Professor Mercy Clinic-Family Medicine/St. Louis College of Pharmacy

SLIDE 2

1. Recognized the impact of the 2018 primary prevention trials to the

body of literature regarding using aspirin (ASA) for primary prevention of cardiovascular disease (CVD)

2. Identify patients that qualify for ASA use for primary prevention of

CVD

3. Recognize the changing role of ASA in the setting of secondary

prevention of CVD

SLIDE 3

▪1897: first synthesized

▪ Commercialized in 1899

▪1974: first trial showing trend of reduced mortality after

acute myocardial infarction (MI) with ASA use

▪1985: FDA approves ASA for secondary prevention

▪ Based on meta-analysis data of individually inconclusive trials

▪1989: ISIS-2

▪ First definitively positive secondary prevention trial with ASA

Lancet 2019;393:2155-67..

SLIDE 4

Circulation 2016;134 (23):1881- 1906.

SLIDE 5

Circulation 2016;134 (23):1881- 1906.

SLIDE 6

SLIDE 7

Aspirin Dose: < 100 mg/day *except BMD and PHS trials

1988 1989 1998

2001 2005 2008 2010 2014 2018

Lancet 2019;393:2155-67..

SLIDE 8

1988 1989 1998

2001 2005 2008 2010 2014 2018

Lancet 2019;393:2155-67..

SLIDE 9

1988 1989 1998

2001 2005 2008 2010 2014 2018

Lancet 2019;393:2155-67..

SLIDE 10

Aspirin to Reduce Risk of Initial Vascular Events (ARRIVE) A Study of Cardiovascular Events iN Diabetes (ASCEND) ASpirin in Reducing Events in the Elderly (ASPREE)

Lancet 2018;392:1036-46.; N Eng J Med 2018;370:1529-39.; N Eng J Med 2018;379:1509-18.

SLIDE 11

Randomized Multicenter Double-Blind Enteric-coated Aspirin 100 mg/day Placebo

SLIDE 12

ARRIVE ASCEND ASPREE

Men aged > 55 years with 2-4 CV risk factors; Women aged > 60 years with > 3 CV risk factors Men and women aged > 40 years with diabetes Caucasians men and women aged > 70 years; Blacks/Hispanics aged > 65 years Germany, Italy, Ireland, Poland, Spain, UK, USA UK Australia, USA n =12,547 n = 15,480 n = 19,114

*CV risk factors: total cholesterol > 200 mg/dL (men) or > 240 mg/dL (women), LDL > 130 mg/dL (men) or > 160 mg/dL (women), HDL < 40 mg/dL, current smoker, systolic blood pressure > 140 mm Hg or on treatment for hypertension, and a family history of cardiovascular heart disease

Lancet 2018;392:1036-46.; N Eng J Med 2018;370:1529-39.; N Eng J Med 2018;379:1509-18.

SLIDE 13

ARRIVE ASCEND ASPREE Age (years) Mean 64 Mean 63 Median 74 Male (%) 71 63 44 White Race (%) 98 97 95 Smoker (%) 29 8 4 Mean SBP (mm Hg) 145 136 139 PMH Hypertension (%) 65 62 75 PMH Hyperlipidemia (%) 58

66

Statin use (%) 43 75 34 Diabetes (%) 100 (94% T2DM) 11 BMI (kg/m2) 28.4 30.8 30 % had BMI > 30

Lancet 2018;392:1036-46.; N Eng J Med 2018;370:1529-39.; N Eng J Med 2018;379:1509-18.

SLIDE 14

ARRIVE ASCEND ASPREE Primary

First composite CV event First composite CV event Death, dementia

r persistent

physical disability

Key Secondary

Individual CV event

components

Cancer rates
Serious adverse

effects (including bleeding)

Individual CV

event components

Major

bleeding

GI cancer rates
First

composite CV event

Major

bleeding

Lancet 2018;392:1036-46.; N Eng J Med 2018;370:1529-39.; N Eng J Med 2018;379:1509-18.

SLIDE 15

Lancet 2018;392:1036-46.

SLIDE 16

Lancet 2018;392:1036-46.

SLIDE 17

Aspirin (n=6270) Placebo (n=6276) Any GI bleed 61 (0.97%) 29 (0.46%) Severe 4 (0.06%) 2 (0.03%) Moderate 15 (0.24%) 5 (0.08%) Mild 42 (0.67%) 22 (0.35%) Hemorrhagic stroke 8 (0.13%) 11 (0.18%)

Lancet 2018;392:1036-46.

p=0.0007

SLIDE 18

N Eng J Med 2018;370:1529-39.

SLIDE 19

N Eng J Med 2018;370:1529-39.

SLIDE 20

N Eng J Med 2018;370:1529-39.

SLIDE 21

N Eng J Med 2018;379:1509-18.

SLIDE 22

N Eng J Med 2018;379:1509-18.

SLIDE 23

N Eng J Med 2018;379:1509-18.

SLIDE 24

ARRIVE ASCEND ASPREE Hazard Ratio 0.99 (95% CI 0.80- 1.24; p=0.95) Rate Ratio 0.94 (95% CI 0.85- 1.04) Hazard Ratio 1.14 (95% CI 1.01- 1.29)

Lancet 2018;392:1036-46.; N Eng J Med 2018;370:1529-39.; N Eng J Med 2018;379:1509-18.

SLIDE 25

▪ Lower event rate overall

▪ Adding to concerns that risk calculators developed with older data might

verestimate risk

▪ Impact better overall blood pressure and cholesterol management ▪ Screening, detection and treatment of CV events

▪ Adherence

▪ Some differences between the intent-to-treat vs per protocol results for the

ARRIVE trial

▪ Difficulty capturing outside of trial aspirin use

▪ Generalizability

▪ Reflective of current patient population and practice

SLIDE 26

JAMA 2019;321:277-87.

Number Needed to Treat: 265 Number Needed to Harm: 210

SLIDE 27

1989 2002 2009 2015 2016 2019

Lancet 2019;393:2155-67..

2014 2003

SLIDE 28

Recommendations for Aspirin Use COR LOE Recommendations IIb A

Low-dose aspirin (75-100 mg orally daily) might be considered for the primary prevention of ASCVD among select adults 40 to 70 years of age who are at higher ASCVD risk but not at increased bleeding risk

III: Harm B-R

Low-dose aspirin (75-100 mg orally daily) should not be administered on a routine basis for the primary prevention of ASCVD among adults > 70 years of age

III: Harm C-LD

Low-dose aspirin (75-100 mg orally daily) should not be administered for the primary prevention of ASCV among adult of any age who are at increased risk of bleeding

JACC 2019;74:e177-232. COR = Class of Recommendation; LOE = Level of Evidence

SLIDE 29

SLIDE 30

▪ Optimal daily dose of ASA for long-term secondary prevention of CVD is unclear ▪ Evidence suggests that ASA doses between 75-100 mg/day have the same CVD

benefit as higher ADA doses (i.e. >182 mg/day) but lower bleeding risk

▪ ASA nonresponse and resistance

▪ Obesity ▪ Diabetes ▪ Enteric-coating

▪ Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term

Effectiveness (ADAPTABLE) trial

▪ N ~ 20,000 ▪ ASA 81 mg/day vs 325 mg/day for secondary prevention of CVD ▪ Scheduled to be completed at end of 2019

Circulation 2016;134:1881-1906.

SLIDE 31

▪ ASA has been the backbone of antiplatelet therapy for the past three

decades

▪ Recent evidence has began to question if ASA should be the

preferred long-term treatment for secondary prevention of CVD

▪ WOEST trial (duel therapy vs triple therapy) ▪ TWILIGHT trial

▪ Role of direct oral acting anticoagulant (DOAC)

▪ COMPASS trial

Circulation 2016;134:1881-1906.

SLIDE 32

N Engl J Med September 26, 2019; published ahead of print.

SLIDE 33

Ticagrelor Monotherapy (n=3555) Ticagrelor + ASA (n=3564) Age (years) 65 65 Female (%) 24 24 BMI (kg/m2) 28.6 28.5 Prior PCI (%) 29 29 Multivessel disease (%) 64 62 Indication for PCI (%) Asymptomatic 7 6 Stable angina 30 28 Unstable angina 35 35 NSTEMI 29 31

N Engl J Med September 26, 2019; published ahead of print.

SLIDE 34

▪ Primary Outcome

▪ Bleeding Academic Research

Consortium (BARC) type 2,3, or 5 bleeding

▪ BARC types range from 0 (no

bleeding) to 5 (fetal bleeding)

▪ Type 4 is excluded from this trial as

it perioperative CABG-related bleeding

N Engl J Med September 26, 2019; published ahead of print.

SLIDE 35

▪Secondary Outcome

▪ Death for any cause, nonfatal

MI, or nonfatal stroke

▪ Met pre-defined statistical

non-inferiority

N Engl J Med September 26, 2019; published ahead of print.

SLIDE 36

Randomized Multicenter Double-Blind Rivaroxaban + Aspirin (2.5 mg BID + 100 mg/day) Rivaroxaban (5 mg BID) Aspirin (100 mg/day)

N Engl J Med 2017; 377:1319-30.

SLIDE 37

Rivaroxaban + Aspirin (n = 9152) Rivaroxaban Alone (n = 9117) Aspirin Alone (n = 9126)

Age (years) 68 68 68 Female (%) 23 22 22 Smokers (%) 22 21 22 Hypertension (%) 76 75 75 Prior MI (%) 62 62 62 On lipid-lowering medication (%) 90 90 89

N Engl J Med 2017; 377:1319-30.

SLIDE 38

N Engl J Med 2017; 377:1319-30.

SLIDE 39

▪Major Bleeding

▪ Rivaroxaban + ASA (n=9152): 228 (3.1%) ▪ Rivaroxaban alone (n=9126): 255 (2.8%) ▪ ASA alone (n=9126): 170 (1.9%) ▪ Rivaroxaban + ASA vs ASA alone: HR 1.70 (95% CI 1.40-2.05), p <

0.001

▪ Rivaroxaban alone vs ASA alone: HR 1.51 (95% CI 1.25-1.84), p <

0.001

N Engl J Med 2017; 377:1319-30.

SLIDE 40

▪ Stop using aspirin for primary prevention for the majority of patients

▪ Target discontinuation of ASA in those over the age of 70 years ▪ Select patients with diabetes aged 40-70 years with a increased ASCVD (i.e. >

20% 10-year risk) could potentially benefit from aspirin for primary prevention ▪ A comprehensive approach to primary prevention of CVD is needed

▪ Diet and physical activity modifications ▪ Weight reduction ▪ Smoking cessation ▪ Blood pressure control ▪ Statin use

▪ Aspirin remains the cornerstone of secondary prevention of CVD

SLIDE 41